VIM and hepatocellular carcinoma: Those results demonstrates that ANX1 may play a pivotal pole in increasing the metastatic potential of cancer cells and that ANX1 may serve as a biomarker for the aggressive phenotype of HCC cells in conjunction with vimentin.